-
Conatus Pharmaceuticals Surges 25% Following Positive Results In Phase 2 Study
Wednesday, January 6, 2016 - 9:45am | 300Shares of Conatus Pharmaceuticals Inc (NASDAQ: CNAT), a small-cap biopharmaceutical company focused on developing medicines to treat liver diseases, were trading higher by 25 percent at $3.61 early Wednesday morning. Conatus Pharmaceuticals announced after Tuesday's market close that a three-month...